| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9008208 | International Immunopharmacology | 2005 | 4 Pages |
Abstract
The use of tacrolimus after liver transplantation resulted in a decreased rate of graft loss over the long-term. An increased number of de novo malignancies in the ciclosporin-based group may be attributable to the use of ATG as induction therapy.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
S. Jonas, R. Neuhaus, G. Junge, J. Klupp, T. Theruvat, J.M. Langrehr, U. Settmacher, P. Neuhaus,